Although SCCOHT is characterized by low tumor mutation burden, recent studies have indicated that the tumor microenvironment of SCCOHT is similar to other immunogenic tumors that respond to checkpoint blockade [37, 40, 63], suggesting that mutations in the subunits of the SWI/SNF complex may contribute to immunotherapy sensitivity. This evidence concerns the gene SMARCA1 and neoplasm.